taxanes in metastatic breast cancer - Alberta Health Services
taxanes in metastatic breast cancer - Alberta Health Services
taxanes in metastatic breast cancer - Alberta Health Services
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CLINICAL PRACTICE GUIDELINE BR-001<br />
44. Slamon DJ, Leyland-Jones B, Shak S, Fuchs HH,<br />
Paton V, Bajamonde A, et al. Use of chemotherapy<br />
plus a monoclonal antibody aga<strong>in</strong>st HER2 for <strong>metastatic</strong> <strong>breast</strong> <strong>cancer</strong> that over-expresses HER2. N<br />
Engl J Med 2001;344:783-792.<br />
45. Gaspar<strong>in</strong>i G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, et al. Randomized<br />
phase II trial of<br />
weekly paclitaxel versus trastuzumab plus weekly paclitaxel as first l<strong>in</strong>e therapy of<br />
patients with Her-2<br />
positive advanced <strong>breast</strong> <strong>cancer</strong>. Breast Cancer Res Treat 2007;101:355-365.<br />
46. Forbes JF, Pienkowski T, Valero V, Eiermann W, M<strong>in</strong>ckwitz GV, Mart<strong>in</strong> M, et al. On<br />
behalf of the<br />
BCIRG007 <strong>in</strong>vestigators. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or<br />
without carboplat<strong>in</strong> first l<strong>in</strong>e <strong>in</strong> HER2 positive <strong>metastatic</strong> <strong>breast</strong> <strong>cancer</strong> (MBC)<br />
ASCO meet<strong>in</strong>g abstracts<br />
2006.<br />
47. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study<br />
of trastuzumab, paclitaxel, and carboplat<strong>in</strong> compared with trastuzumab and paclitaxel <strong>in</strong> women with<br />
HER-2-overexpress<strong>in</strong>g <strong>metastatic</strong> <strong>breast</strong> <strong>cancer</strong>. J Cl<strong>in</strong> Oncol. 2006 Jun 20;24(18):2786-92.
Change language